Citations 1
Genetic Testing in the Management of Adult CKD
Chebib, Fouad T. , Wang, Xiangling , Udani, Suneel M. , Westemeyer, Maggie , Clark, Dinah, Zhang, Zhiji, Rasouly, Hila Milo , Kolupaeva, Victoria, Mizani, Mohammad R. , Faravardeh, Arman , Kotte, Sri, Punj, Sumit , Chapman, Steven L. , Schneider, Ronen, Tabriziani, Hossein , Bhorade, Sangeeta , Gharavi, Ali G. , Kolupaeva, Victoria , Bloom, Michelle S , Milo Rasouly, Hila , Mizani, Mohammad R , Dossabhoy, Neville R , Faravardeh, Arman , Demko, Zachary P , Punj, Sumit , Chapman, Steven L , Rabinowitz, Matthew , Tabriziani, Hossein , Bhorade, Sangeeta , Dahl, Neera K , Westemeyer, Maggie , Kolupaeva, Victoria , Chebib, Fouad T , Wang, Xiangling , Udani, Suneel M. , Clark, Dinah, Zhang, Zhiji, Kotte, Sri, Schneider, Ronen, Gharavi, Ali G.
Journal of the American Society of Nephrology | December 3, 2025 | Volume: 37 | Issue: 4 | Pages: 777-789
Key Points Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy. Background CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing. Methods The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point. Results In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding. Conclusions Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.